New Antibody-Drug cocktail targets tough colorectal cancer
NCT ID NCT07503756
First seen Jun 25, 2026 · Last updated Jun 25, 2026
Summary
This study tests a new drug called JS212, which is designed to target two proteins on cancer cells (EGFR and HER3) and deliver a chemotherapy-like payload directly to them. It is being tested in combination with other standard cancer drugs in 80 adults with metastatic colorectal cancer that has not been treated before. The goal is to see if these combinations are safe and can shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai East Hospital
RECRUITINGShanghai, Shanghai Municipality, 200123, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
JS212 (bispecific antibody-drug conjugate targeting EGFR and HER3) combined with capecitabine, bevacizumab, oxaliplatin, and/or JS207
What this could lead to
If successful, this could lead to a new treatment option for people with metastatic colorectal cancer that has not spread after initial therapy.
What could go wrong
This is an early Phase 2 trial with only 80 participants, so results may not apply to everyone. The combination therapies may cause side effects or not work better than existing treatments.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.